Key result
Fibrinolysis prevents hemodynamic collapse in intermediate-risk PE but increases major bleeding and stroke.
Why the study?
Does fibrinolytic therapy prevent hemodynamic decompensation in patients with intermediate-risk pulmonary embolism?
Does fibrinolytic therapy prevent hemodynamic decompensation in patients with intermediate-risk pulmonary embolism?
Fibrinolytic therapy prevents hemodynamic decompensation in intermediate-risk pulmonary embolism but significantly increases the risk of major hemorrhage and stroke.
Answers are grounded in this paper and cite their sources.
Reserve fibrinolysis for high-risk cases; confirms net harm with routine use in intermediate-risk pulmonary embolism.
In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2014) studied this question. Fibrinolytic therapy prevented hemodynamic decompensation in patients with intermediate-risk pulmonary embolism, but increased the risk of major hemorrhage and stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: